In a groundbreaking new report sent to every member of Parliament, the Perseus group - a team of experts from the fields of medicine, pharmaceutical regulation and safety management - has set out in detail the numerous concerns raised by experts globally about the vaccines and the specific concerns about the U.K.'s Medicines and Healthcare products Regulatory Authority (MHRA) responsible for giving them the green light.
"MHRA announced that it has morphed from 'watchdog' to 'enabler'. Would anyone be concerned if that was said by the Office for Nuclear Regulation, the Civil Aviation Authority or the Defence Safety Regulator," Perseus group spokesman Nick Hunt said.
The evident lack of interest in post-rollout issues with the COVID-19 vaccines was highlighted as particularly shocking.
Before the rollout in December 2020 the MHRA promised a rigorous "four-strand proactive vigilance" of Covid vaccine safety. But freedom of information requests have revealed that very little of this work is being done. The single report supplied from the "Targeted Active Monitoring" strand was 15 months old, from August 2021, the report says.
The group slams the MHRA for failing to act on problems with the AstraZeneca vaccine for months after many other national regulators suspended and withdrew it for certain age groups. The MHRA also continued to ignore "ever increasing evidence of Covid vaccine risks, notably blood clotting, heart inflammation, neurological conditions, immune downgrading and menstrual disorders", the report states.
The secrecy around Covid vaccines in particular is blasted, with key documents on risks versus benefits that are routinely published for other medicines being absent for Covid vaccines. "This compromised informed consent," notes the group.
Other problems include that the MHRA authorised the mRNA products as vaccines, which have lower regulatory requirements, rather than properly classifying them as novel genetic products, and that it failed to identify and address problems with manufacturing and quality control, leading to batch quality problems.
More general criticisms of the agency include that it assesses the safety of a medicine relative to its benefit rather than in absolute terms, which the report likens to the Nuclear Regulator saying, "Our nuclear power station is safe because it has fewer contaminated water leaks than other stations".
The regulator also nowhere defines the tolerable rate of fatal and serious side-effects of new medicines, which the report blames for its slowness to act when problems emerge.
Freedom of information requests also reveal, alarmingly, that the MHRA has no process for investigating Yellow Card reports of adverse events potentially linked to the COVID-19 vaccines or other medicines. This, the report highlights, is just one facet of a broader lack of the kind of robust safety management systems and processes that are standard in other safety critical sectors such as aviation, defence, nuclear, oil and gas and rail. Similarly, freedom of information requests reveal that there has never been a safety audit of MHRA.
The report's findings are damning and expose a regulator not fit for purpose and clearly failing in its basic aim of keeping the public safe from harmful medical products....<<<Read More>>>...